Stage 4 invasive ductal carcinoma: metastatic disease with bone involvement managed successfully
This breast cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- ER <1%; PR 0%; HER2 score 3+; Ki-67 60%
- Sex
- Female
- Spread to
- bone (12th thoracic vertebra/T12)
- Treatment
- chemotherapy, targeted therapy, surgery and supportive care
- Outcome
- Responding Well
Treatment course, step by step
- Doxorubicin + cyclophosphamide (AC) and trastuzumab + docetaxel + pertuzumab [T12 bone metastasis became less clear, breast tumor did not improve]
- surgery postponed because of thyrotoxicosis from clinically diagnosed TSH-PitNET
- lanreotide normalized pituitary and thyroid function after 1 month
- trastuzumab deruxtecan (T-DXd) after breast tumor enlarged to 56 mm [reduced to 16 mm after 4 months]
- locoregional surgery/mastectomy 5 months after starting T-DXd [pathologic complete response in breast specimen]
- postoperative chemotherapy continued to prevent recurrence/metastasis; pituitary surgery deferred until chemotherapy completion.
What happened, in summary
A 52-year-old woman with a long history of thyroid disease noticed a right breast mass 2 years before the case report and sought breast evaluation 1 year later. Examination found a hard, poorly mobile 52 mm right breast mass. Mammography and ultrasound showed an irregular spiculated lesion, and needle biopsy confirmed invasive ductal carcinoma with fatty invasion. The tumor was ER
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Breast Cancer 295 stories
- Stage 4 HER2 Positive Breast Cancer 53 stories
- HER2 Positive Breast Cancer 136 stories
- Chemotherapy for Breast Cancer 726 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer